These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 22333148)

  • 1. [Correlation of elevated serum CXCL16 and severity of acute coronary syndromes in male elders].
    Zhuge X; Wang LL; Sun N; Zhang Y
    Zhonghua Yi Xue Za Zhi; 2011 Dec; 91(46):3271-4. PubMed ID: 22333148
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating soluble SR-PSOX/CXCL16 as a biomarker for acute coronary syndrome -comparison with high-sensitivity C-reactive protein.
    Mitsuoka H; Toyohara M; Kume N; Hayashida K; Jinnai T; Tanaka M; Kita T
    J Atheroscler Thromb; 2009 Oct; 16(5):586-93. PubMed ID: 19729872
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Soluble CXCL16 predicts long-term mortality in acute coronary syndromes.
    Jansson AM; Aukrust P; Ueland T; Smith C; Omland T; Hartford M; Caidahl K
    Circulation; 2009 Jun; 119(25):3181-8. PubMed ID: 19528340
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum CXCL16 as a Novel Biomarker of Coronary Artery Disease in Type 2 Diabetes Mellitus: a Pilot Study.
    Zhou F; Wang J; Wang K; Zhu X; Pang R; Li X; Zhu G; Pan X
    Ann Clin Lab Sci; 2016; 46(2):184-9. PubMed ID: 27098626
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CXC chemokine ligand 16 as a prognostic marker in patients with intermediate coronary artery lesions: a 2-year follow-up study.
    Tan K; Lu S; Chen Y; Song X; Wu X; Jin Z; Yuan F; Zhou Y; Li H; Yang T; Zhou Y; Li Z; Chen F; Zhang S; Guo L; Wang W; Zhao Q; Huo Y; Yang X; Liu J; Chen B; Yan H; Li H; Ke Y; Chen K; Shi D
    Tohoku J Exp Med; 2011 Apr; 223(4):277-83. PubMed ID: 21467783
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Decreased plasma CXCL16/SR-PSOX concentration is associated with coronary artery disease.
    Sheikine Y; Bang CS; Nilsson L; Samnegård A; Hamsten A; Jonasson L; Eriksson P; Sirsjö A
    Atherosclerosis; 2006 Oct; 188(2):462-6. PubMed ID: 16378611
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased serum CXCL16 level is a marker for acute coronary syndromes.
    Sun Y; Chang Z; Zhang S
    Arch Med Res; 2008 Apr; 39(3):332-7. PubMed ID: 18279707
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Soluble CXCL16 and risk of myocardial infarction: The HUNT study in Norway.
    Laugsand LE; Åsvold BO; Vatten LJ; Janszky I; Platou C; Michelsen AE; Arain F; Damås JK; Aukrust P; Ueland T
    Atherosclerosis; 2016 Jan; 244():188-94. PubMed ID: 26649903
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multimarker risk assessment including osteoprotegerin and CXCL16 in acute coronary syndromes.
    Jansson AM; Hartford M; Omland T; Karlsson T; Lindmarker P; Herlitz J; Ueland T; Aukrust P; Caidahl K
    Arterioscler Thromb Vasc Biol; 2012 Dec; 32(12):3041-9. PubMed ID: 23023373
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemokine SR-PSOX/CXCL16 expression in peripheral blood of patients with acute coronary syndrome.
    Yang HL; Xu YY; DU LF; Liu CH; Zhao Q; Wei WJ; You Y; Quan ZH
    Chin Med J (Engl); 2008 Jan; 121(2):112-7. PubMed ID: 18272035
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circulating CXCL16 is related to the severity of coronary artery stenosis.
    Yi GW; Zeng QT
    Arch Med Res; 2008 Jul; 39(5):531-5. PubMed ID: 18514099
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CXCL16 is a marker of inflammation, atherosclerosis, and acute coronary syndromes in humans.
    Lehrke M; Millington SC; Lefterova M; Cumaranatunge RG; Szapary P; Wilensky R; Rader DJ; Lazar MA; Reilly MP
    J Am Coll Cardiol; 2007 Jan; 49(4):442-9. PubMed ID: 17258089
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CXCL16 is a surrogate marker of inflammatory bowel disease.
    Lehrke M; Konrad A; Schachinger V; Tillack C; Seibold F; Stark R; Parhofer IG; Broedl UC
    Scand J Gastroenterol; 2008 Mar; 43(3):283-8. PubMed ID: 18938659
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma vaspin concentrations are decreased in acute coronary syndrome, but unchanged in patients without coronary lesions.
    Zhang B; Peng W; Li H; Lu Y; Zhuang J; Wang K; Su Y; Xu Y
    Clin Biochem; 2013 Oct; 46(15):1520-5. PubMed ID: 23850850
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Soluble CXCL16 and long-term outcome in acute ischemic stroke.
    Ueland T; Smedbakken LM; Hallén J; Atar D; Januzzi JL; Halvorsen B; Jensen JK; Aukrust P
    Atherosclerosis; 2012 Jan; 220(1):244-9. PubMed ID: 22055341
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Elevated levels of platelet-monocyte aggregates and related circulating biomarkers in patients with acute coronary syndrome.
    Wang J; Zhang S; Jin Y; Qin G; Yu L; Zhang J
    Int J Cardiol; 2007 Feb; 115(3):361-5. PubMed ID: 16887214
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circulating soluble adhesion molecules ICAM-1 and VCAM-1 and their association with clinical outcome, troponin T and C-reactive protein in patients with acute coronary syndromes.
    Postadzhiyan AS; Tzontcheva AV; Kehayov I; Finkov B
    Clin Biochem; 2008 Feb; 41(3):126-33. PubMed ID: 18061588
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of serum levels of inflammatory markers in patients with coronary vasospasm without significant fixed coronary artery disease versus patients with stable angina pectoris and acute coronary syndromes with significant fixed coronary artery disease.
    Hung MJ; Cherng WJ; Cheng CW; Li LF
    Am J Cardiol; 2006 May; 97(10):1429-34. PubMed ID: 16679078
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The expression of transmembrane and soluble CXCL16 and the relation with interferon-alpha secretion in patients with Behçet's disease.
    Yilmaz S; Cinar M; Pekel A; Simsek I; Musabak U; Erdem H; Pay S
    Clin Exp Rheumatol; 2013; 31(3 Suppl 77):84-7. PubMed ID: 24064021
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Soluble CXCL16 in preoperative serum is a novel prognostic marker and predicts recurrence of liver metastases in colorectal cancer patients.
    Matsushita K; Toiyama Y; Tanaka K; Saigusa S; Hiro J; Uchida K; Inoue Y; Kusunoki M
    Ann Surg Oncol; 2012 Jul; 19 Suppl 3():S518-27. PubMed ID: 21845497
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.